A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9 |

Ccc.med.uni-goettingen.de

Studienliste für das Tumorboard: Brusttumore

Breast cancer

A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative
(ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer –AEZS-108-049
local PI:
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot

Follow-up Studies: Breastcancer

A randomised three-arm multi-centre comparison of 1 year and 2-years of
Herceptin® versus no Herceptin® in women with HER2-positive primary breast
cancer who have completed adjuvant chemotherapy-HERA
PI:
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot
A Prospectively Randomized Phase III Trial, studying the benefits of adjuvant
sequential vs. combined taxan based chemotherapy and different durations of
Zoledronate treatment in early breast cancer: Success Trial-SUCCESS A
PI:
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot
Prospectively randomized phase III trial, studying the benefits of adjuvant sequential
anthracycline axane based vs. anthracycline free taxane based chemotherapy,
followed by a dietary intervention study in early, HER2-negative breast
cancer SUCCESS-C –
Klinische Studien Tumorboard Brusttumore
[email protected]
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib,
trastuzumab, their sequence and their combination in patients with HER2/ErbB2
positive primary breast cancer. Adjuvante Lapatinib u./o. Trastuzumab Treatment
Optimisation (ALLTO)
PI:
Dr. M. Hellriegel (Senior Assistent Medical Director) [email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot
A phase III trials program exploring the integration of Bevacizumab, Everolimus
(RAD001),and Lapatinib into current neoadjuvant chemotherapy regimes for primary
breast cancer -GeparQuinto.
PI:

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients withHER2-
Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing
Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus
Bevacizumab. Bevacizumab with Trastuzumab Adjuvant Therapy in HER2+ Breast
Cancer (Beth)
PI:
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot
Randomised comparison of adjuvant Docetaxel / Cyclophosphamide with sequential
adjuvant EC / Docetaxel chemotherapy in patients with HER2/neu negative early
breast cancer 6 x TC vs. 4 x EC-> 4 x Doc. Plan B
Klinische Studien Tumorboard Brusttumore
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot
A phase III multicenter double blind randomized trial of celecoxib versus placebo in
primary breast cancer patients (REACT-Randomised European Celecoxib Trial)

PI:
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot
An international multi-centre study of tamoxifen vs anastrozole in
postmenopausal women with Ductal Carcinoma in Situ (IBIS-DCIS)

PI:
[email protected] http://www.uni-frauenklinik-goettingen.de/ ->Studienangebot Klinische Studien Tumorboard Brusttumore

Source: http://www.ccc.med.uni-goettingen.de/images/projekt/contact/Studien_Brusttumore_01-2013.pdf